1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Bristol-Myers Squibb Acquires 2seventy bio

M&A Deal Summary

Bristol-Myers Squibb Acquires 2seventy bio

On March 10, 2025, Bristol-Myers Squibb acquired life science company 2seventy bio for 286M USD

Acquisition Highlights
  • This is Bristol-Myers Squibb’s 24th transaction in the Life Science sector.
  • This is Bristol-Myers Squibb’s 18th largest (disclosed) transaction.
  • This is Bristol-Myers Squibb’s 21st transaction in the United States.
  • This is Bristol-Myers Squibb’s 5th transaction in Massachusetts.

M&A Deal Summary
Date 2025-03-10
Target 2seventy bio
Sector Life Science
Buyer(s) Bristol-Myers Squibb
Deal Type Add-on Acquisition
Deal Value 286M USD
Advisor(s) Goldman Sachs (Financial)
Goodwin Procter (Legal)

Target

2seventy bio

Cambridge, Massachusetts, United States
2seventy bio is an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. 2seventy bio was formed in 2021 and is based in Ottawa, Ontario.

Search 205,240 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bristol-Myers Squibb

Princeton, New Jersey, United States
Category Company
Founded 1887
Sector Life Science
Employees34,100
Revenue 45.0B USD (2023)
DESCRIPTION

Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes. The majority of Bristol-Myers Squibb's revenue comes from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and metabolics. Bristol-Myers Squibb was incorporated in 1887 and is based in Princeton, New Jersey.

DEAL STATS #
Overall 24 of 24
Sector (Life Science) 24 of 24
Type (Add-on Acquisition) 22 of 22
State (Massachusetts) 5 of 5
Country (United States) 21 of 21
Year (2025) 1 of 1
Size (of disclosed) 18 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-26 RayzeBio

San Diego, California, United States

RayzeBio is building a radiopharmaceutical therapeutics (RPT) company to treat various cancers, with its lead program in a Phase 3 clinical trial. The company has created a pipeline of multiple drug candidates in therapeutic areas with significant market opportunities. Much like antibody-drug conjugates emerged as a new and transformative treatment modality in certain cancers, it sees an opportunity for innovative radiopharmaceutical therapeutics to follow a similar path. RayzeBio is based in San Diego, California.

Buy $4.1B
Mergr

Product

Company

Legal